PC
SLXNW

Periscope Capital’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Periscope Capital’s Portfolio SLXNW Stock Details SLXNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-87,169
Closed -$6.67K – 266
2025
Q1 		$6.67K Hold
87,169
– – ﹤0.01% 181
2024
Q4 		$2.96K Sell
87,169
-17,374
-17% -$698 ﹤0.01% 184
2024
Q3 		$5.3K Buy
+104,543
New +$6.05K ﹤0.01% 210

Other funds holding SLXNW

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
HP
Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SBLIC
Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Periscope Capital's SLXNW Position: Q2 2025 in Review

Periscope Capital sold out of Silexion Therapeutics Warrant (SLXNW) in Q2 2025, closing a stake of 87,169 shares — an estimated $6.67K sold.

Periscope Capital first reported a position in SLXNW in Q3 2024 and held it in 3 quarters. The position peaked at $6.67K in Q1 2025. 22 funds tracked by Wall St. Rank hold SLXNW as of Q2 2025.

  • Periscope Capital reported no remaining Silexion Therapeutics Warrant position as of Q2 2025 after selling out during the quarter.
  • Periscope Capital sold 87,169 Silexion Therapeutics Warrant shares in Q2 2025, an estimated $6.67K.
  • Periscope Capital first reported a position in Silexion Therapeutics Warrant in Q3 2024 and held it in 3 quarters.
  • Periscope Capital's Silexion Therapeutics Warrant position peaked at $6.67K in Q1 2025.
  • 22 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q2 2025.

Based on Periscope Capital's 13F filing for Q2 2025, filed 14 Aug 2025.